TRCT
ZBIO

Tower Research Capital (TRC)’s ProShares UltraPro Short NASDAQ Biotechnology ZBIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-8,651
Closed -$79K – 4422
2019
Q4 		$79K Buy
8,651
+6,667
+336% +$81K 0.01% 1082
2019
Q3 		$33K Buy
+1,984
New +$29.5K ﹤0.01% 2122
2019
Q2 		– Sell
-47
Closed -$1K – 4663
2019
Q1 		$1K Buy
+47
New +$684 ﹤0.01% 3697
2018
Q2 		– Sell
-1,535
Closed -$32K – 4311
2018
Q1 		$32K Buy
+1,535
New +$30.1K ﹤0.01% 1943
2016
Q3 		– Sell
-22
Closed -$1K – 4876
2016
Q2 		$1K Sell
22
-2,411
-99% -$148K ﹤0.01% 4279
2016
Q1 		$177K Sell
2,433
-7,179
-75% -$532K 0.03% 349
2015
Q4 		$394K Buy
9,612
+9,376
+3,973% +$461K 0.06% 136
2015
Q3 		$16K Buy
+236
New +$10.7K ﹤0.01% 1947

Other funds holding ZBIO

Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Tower Research Capital (TRC)'s ZBIO Position: Q1 2020 in Review

Tower Research Capital (TRC) sold out of ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) in Q1 2020, closing a stake of 8,651 shares — an estimated $79K sold.

Tower Research Capital (TRC) first reported a position in ZBIO in Q3 2015 and held it in 8 quarters. The position peaked at $394K in Q4 2015. 1 fund tracked by Wall St. Rank holds ZBIO as of Q1 2020.

  • Tower Research Capital (TRC) reported no remaining ProShares UltraPro Short NASDAQ Biotechnology position as of Q1 2020 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 8,651 ProShares UltraPro Short NASDAQ Biotechnology shares in Q1 2020, an estimated $79K.
  • Tower Research Capital (TRC) first reported a position in ProShares UltraPro Short NASDAQ Biotechnology in Q3 2015 and held it in 8 quarters.
  • Tower Research Capital (TRC)'s ProShares UltraPro Short NASDAQ Biotechnology position peaked at $394K in Q4 2015.
  • 1 fund tracked by Wall St. Rank held ProShares UltraPro Short NASDAQ Biotechnology as of Q1 2020.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2020, filed 15 May 2020.